^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.
Source:
Title:
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Excerpt:
...Cmax of Erlotinib and Its Metabolite OSI-420`Erlotinib Tmax`AUC Time 0-infinite (AUCinf) of Erlotinib and Its Metabolite OSI-420`Number of Positive Mutations of EGFR and Downstream Pathways`Ability of Erlotinib to Inhibit EGFR Signaling`Correlation Between Standard Magnetic Resonance Imaging and Investigational Radiologic Techniques in Assessing Tumor Response to This Treatment`To Prospectively Investigate the Technical Factors Involved in Planning and Administering Conformal Fractionated RT as Outlined in This Study, and to Correlate RT Dosimetry With Patterns of Failure, Standard and Investigational Imaging and Toxicity`Plasma and CSF Levels of VEGF, bFGF, and SDF1`Number of Participants Experiencing Grade 3 or 4 Toxicity Events...
Trial ID:
Source:
Title:
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Excerpt:
...- EGFRvIII mutation detected on pretreatment tissue from at least 1 prior surgery....
Trial ID:
Less C2 evidence
Source:
Title:
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
Excerpt:
Our results suggest extracellular missense mutations as a novel mechanism for oncogenic EGFR activation and may help identify patients who can benefit from EGFR kinase inhibitors for treatment of glioblastoma.
DOI:
10.1371/journal.pmed.0030485
